Health Trials

Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

3

Review clinical trials related to Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).

Participants needed: 30
Trial details
Phase: Phase 1Age: 0-18Biological sex: AllType: InterventionalSponsor: Autolus LimitedUpdated: Mar 2, 2026Locations: 8
Eligibility criteria

< 18 years old at screening [+4]

Diagnosis of chronic myelogenous leukemia in lymphoid blast crisis. [+5]

Read more
Participants needed: 33
Trial details
Phase: Phase 1Age: 3-25Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Updated: May 22, 2025Locations: 8
Eligibility criteria

The patient himself/herself , and/or his/her legal guardian, agree to participat... [+2]

Active CNS involvement by malignancy； [+3]

Read more
Status: Recruiting

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.

Participants needed: 10
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Institute of Hematology and Blood Transfusion, Czech RepublicUpdated: Jan 6, 2025Locations: 1
Eligibility criteria

B-ALL refractory to treatment or in the second or subsequent relapse (hematologi... [+6]

Known hypersensitivity to any component of the Investigational Medicinal Product... [+36]

Read more